SGLT2 inhibitors, GLP-1 receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors are three new classes of glucose­lowering agents for patients with DKD (159–161). The gene discussed is DPP4; the disease is diabetic kidney disease.